Compulsory Licensing:
|
|
- Tabitha Carpenter
- 5 years ago
- Views:
Transcription
1 HESO 449B Compulsory Licensing: An effective tool to increasing access to essential medicines? Julia Wu Submitted on April 7 th, 2010
2 Realizing that patent protection on pharmaceutical products can restrict access to essential medicines, developing countries in the World Trade Organization (WTO) pushed for the implementation of the Doha Declaration, a declaration which allows countries to override patent laws to protect public health through compulsory licensing. Although the Doha Declaration was implemented and seen as a political win for developing countries, many of those countries were, and still are, hesitant in using the Doha Declaration flexibilities, especially in issuing compulsory licences. In this paper, I will explore the effectiveness of compulsory licensing and look at its challenges, benefits, and setbacks. I will also examine the amendments that have been made to date as well as suggestions to future amendments in improving the feasibility of using compulsory licensing as a tool to increasing access to essential medicines. Before I jump into discussion on compulsory licensing, I will go over some important and relevant background information. As of July 23rd 2008, 153 countries were members in the World Trade Organization (WTO)[1], an organization which deals with the rules of trade between nations at a global or near-global level. [2] Member countries of the WTO must adhere with the agreements set in place by the organization; this includes the General Agreement on Tariffs and Trade (GATT) established in 1948 as well as the more recent Trade Related aspects of Intellectual Property Rights (TRIPs) agreement in 1995 [3]. Of the 18 WTO agreements, the TRIPs agreement was seen to have the greatest impact on pharmaceutical products and access to medicines. The agreement required all WTO members to provide 20 years of patent protection after a patent has first been filed; this includes both process and product patents on pharmaceutical products. [4] Having an invention patented grants the inventor exclusive rights to the invention. Patent holders have the capability to set the price of their patented product to any value they desire because market competition is eliminated. As pharmaceutical products were granted patent protection, drugs became unaffordable to many people in developing countries.
3 Prior to TRIPs, not only was there a much shorter duration in which a patent is under protection (5-7 years in least developed countries and years in developing and developed countries after the patent has been first filed) [4], but there was also no requirement for WTO members to protect patents on pharmaceuticals (though there were other agreements among countries that protected pharmaceutical patents, it was not included in any WTO agreement and 40 WTO member countries did not have patent protection for pharmaceutical products) [5]. Also pre-trips, many countries did not have protection on product patents though they had protection on process patents [6]. This allowed manufacturers to produce a product that was under patent as long as the procedures used in producing the product were different than those used in producing the patented product. Because the implementation of TRIPs required all countries to protect patents on processes and products, countries were no longer able to reverse engineer drugs and produce them generically at an affordable price. In response to concerns of how the TRIPs agreement can restrict access to affordable and essential medicines in developing populations, the WTO issued the Doha Declaration in November The Declaration affirms that the TRIPS Agreement does not and should not prevent Members from taking measures to protect public health and TRIPs should be interpreted and implemented in a manner supportive of WTO Members' right to protect public health and, in particular, to promote access to medicines for all. [7] Through the declaration, each member has the right to issue compulsory licences in the events of national emergencies, circumstances of extreme urgency or for public non-commercial use. [8] The member government, under their own discretion, determines what constitutes a public health emergency and what medicines they are entitled to produce. Though compulsory licensing existed before the Doha Declaration [9], the process was cumbersome and required consent from the patent holder.
4 Compulsory licensing under the Doha Declaration grants governments or governmentauthorized manufacturers the right to make a patented product without the patent holder s permission [10]. In life-threatening situations, the issuance of a license allows governments to respond quickly in providing affordable and accessible medication. Compulsory licensing is also used as a negotiating tool to lower prices of drugs. Brazil, a country with an estimated 730,000 people living with HIV/AIDS [11] took advantage of compulsory licensing to make treatment more accessible. Between 2002 and 2003, the Brazilian government, by threatening to issue compulsory licenses during price bargains with pharmaceutical companies, was successful in significantly decreasing the cost of medicines. There was an estimated 73% price drop for the drug Efavirenz, 56% for Lopinavir/Ritonavir, and 74% for Nelfinavir [12]. After the more expensive second line drugs came out, Brazilians were unable to afford treatment as drug prices took a steep increase. In 2007, Brazil issued a compulsory license to produce generic versions of Efavirenz [13], a drug that was costing the Brazilian government US$580 per patient per year. Generic versions of Efavirenz were estimated at less than US$170 per patient per year [14]. Though there are merits to compulsory licensing, the terms relating to compulsory licensing under the Doha Declaration have not met the goal of improving accessibility of medicines in many developing populations. Moreover, compulsory licensing may have even strengthened the barrier to medicines access for those who are most in need. Many underdeveloped countries are hesitant in using the Doha flexibilities due to their lack of manufacturing capacity, political repercussions, and negative economic consequences of compulsory licensing. The following sections of this paper will describe the problems associated with compulsory licensing as well as setbacks relating to its amendments. When the Doha Declaration was first implemented, article 31, paragraph (f) of TRIPs states that if compulsory licensing is used, [it] shall be authorized predominantly for the supply of the domestic
5 market of the Member authorizing such use. [15] For many underdeveloped countries, producing drugs domestically is not a viable option as they have little or no pharmaceutical manufacturing capacity. For example, approximately 80% of developing countries lack facilities domestically to produce antiretroviral drugs to combat HIV/AIDS [16]. The WTO s attempt at a solution to this problem came two years after the Doha Declaration. On August 30 th 2003, the WTO revised the provision in article 31 [17] enabling members to issue compulsory licenses to export to countries with limited manufacturing capacity; however, the challenge then shifts to finding willing exporting countries as the August 30 th decision poses complex requirements and lacks business incentives. As of September 2008, only seven WTO members have adopted the August 30 th decision in their domestic legislations to be eligible exporting countries [18]. To date, there has only been one case where the revision was put into practice. In 2007, Canada issued a compulsory licence to allow generic manufacturer Apotex to export Apo TriAvir, a combination drug for HIV treatment, to Rwanda [19]. Though Canada was praised for their leadership in being the first to use the exporting flexibility, the case displayed many setbacks which outweighed its positives. The idea of compulsory licensing is to serve populations who are urgently in need of medical aid but Rwanda did not receive the Apo TriAvir shipment until four years after Apotex first started working on the drug. The delay in providing the medicine was caused by the WTO provisions and Canada s legislation which set out strict outlines relating to eligible drugs that can be exported as well as consent from the patent holder. Because Apo TriAvir is a combination drug and was not on the list of eligible drugs for export, Apotex had to submit further applications to get Apo TriAvir approved. Moreover, the case resulted in huge economic losses for Apotex due to production costs, transaction costs, legislative costs, as well royalties to the patent holder [20]. Another barrier to effective use of compulsory licensing is the TRIPs requirement relating to data exclusivity. The TRIPs Agreement grants the pharmaceutical company who originally produced the
6 patented drug exclusive rights over the test data of the drug. The test data demonstrates the safety, quality, and efficacy of the product, and is needed as a condition for permitting sale or marketing of a pharmaceutical product. [21] As generic manufacturers do not have rights to access the original test data, they would need to compile new tests on their product even though it is chemically identical to the original product. Again, the WTO s vision of compulsory licensing as a tool to provide emergency relief to people in need is defeated as generic pharmaceutical products are delayed in entering the market due to new test compilations along with the subsequent approval applications that are required. Perhaps the biggest concern with compulsory licensing is the ambiguity of its terms introduced in the Doha Declaration. Though the ambiguity is intended to broaden the scope of medical aid that can be provided by not limiting compulsory licenses to specific circumstances, the vague terms in the declaration have led to many questionable actions by WTO members which have hindered the access to medicines for those in need. The TRIPs revisions under the Doha Declaration allow WTO members to override patent laws in the case of a national emergency or other circumstances of extreme urgency [22]. As emergencies and the adequate remuneration to patent holders are defined under the discretion of the member governments, there have been cases where members have been abusing the use of compulsory licences. Countries that have been using the compulsory licensing flexibilities have seen a decrease in foreign direct investment as well as trade retaliation from superpowers like the United States. For developing and underdeveloped countries that are trying to stabilize their economies, foreign direct investment is important in helping their nation evolve, and thus, these nations are hesitant to issue compulsory licenses even if their people are facing genuine health emergencies. Egypt, for example, is a country that heavily supports the use of compulsory licensing. The grounds for issuing compulsory licenses in the Egyptian legislation are vaguely stated and include the right to issue a license if the prices are too high for most consumers or if it is politically burdensome.
7 [23] In 2002, shortly after Pfizer received approval to launch Viagra into the Egyptian market, the Egyptian government, pressured by popular local manufacturers, issued a compulsory license to generically produce Viagra [24]. Viagra, a drug to treat erectile dysfunction, is important but certainly not a drug that is used for public health emergencies. From an economic point of view, the positive health effects through compulsory licensing should outweigh the financial losses for pharmaceutical companies. This was not the case for Pfizer and Viagra in Egypt. After being informed of Egypt s compulsory license for Viagra, Pfizer was angry and halted plans of building a manufacturing facility in Egypt [25]. The Viagra case also discouraged other pharmaceutical companies in investing in Egypt s market. As a result, Egypt s foreign direct investment dropped from $1104 million in 1997 to $428 million in 2002 [26]. Thailand is another country that faced a decrease in foreign direct investment due to excessive use of compulsory licences. Between 2006 and 2007, Thailand s Ministry of Public Health (MOPH) filed three compulsory licenses: two antiretroviral drugs (Efavirenz and Lopinavir/Ritonavir) and a blood thinner for heart disease (Plavix)[27]. Though it is arguable whether or not Plavix puts a big enough impact on public health to issue a compulsory license, the broad terms of the Doha Declaration makes this action fully acceptable. Following the licenses, Abbott, the pharmaceutical company holding patents for the drugs, not only announced that they would no longer register new medicines into Thailand s market, but they also held a campaign to spread false information about Thailand s licensing process stating that Thailand has chosen to break patents on numerous medicines, ignoring the patent system. [28]. Between 2005 and 2007, Thailand s foreign direct investment dropped by $10 billion [29]. Fearing the same social, economic, and political repercussions, developing and least developed countries, especially with their diverse needs, are not comfortable using compulsory licensing. Both Egypt and Thailand are on the United States Watch List for having poor intellectual property
8 protection and are faced with trade sanctions. Furthermore, pharmaceutical companies have lost faith in the compulsory licensing system and do not see the common goal of increasing health access to all as it appears that countries are using the system to their best interests. Even the United States, a country that lobbied heavily against the compulsory licensing flexibilities, issued a license for the drug Cipro fearing the outbreak of Anthrax after the September 11 th incident [30]. The rest of the world was in a major uproar for the United States double standard. Despite the negativity surrounding compulsory licenses, the system can be made feasible. The first step is to get all the parties involved on the same page with the common goal of achieving and sustaining a healthy world. Collaboration among governments, WTO delegates, NGOs and industry is important in reaching this goal. Like any significant change, this needs to happen gradually. Nations can start by amending provisions in their legislation which hinder the access to medicines to not just their own people, but to the world as a whole. For example, the August 30 th decision can be revisited. Generic manufacturer Apotex stated that they would be happy to continue producing drugs for export given that Canada s Access to Medicines Regime (CAMR) is amended [31]. Bill 393, a bill proposed to simplify CAMR, has passed two of the three required government readings to date [32]. The bill, if implemented, would provide a convenient one license system to replace the need for individual drug applications, eliminate the list of eligible drugs to export, and discourages unnecessary legal action [33]. The revisions will likely attract more interest from manufacturers and will pave the way for other well developed nations to export medicines under compulsory licensing. Furthermore, the compulsory licensing terms under the Doha Declaration can be interpreted more consistently if there is a WTO group governing the issuance of compulsory licenses and determining the grounds of a health emergency. With this kind of involvement by the WTO, there is less justification for countries to pose economy-crippling trade sanctions on compulsory licensing users.
9 Developing and underdeveloped countries can then lift their fears of negative consequences and use compulsory licensing confidently. Consistency in compulsory licensing would also establish faith in the system for pharmaceutical companies. Ultimately, compulsory licensing has yet to be proved a solution to the TRIPs concerns, however, with groups cooperating to balance private intellectual property interests with public welfare, compulsory licensing can be effective in increasing access to essential medicines. For developing and underdeveloped countries, compulsory licensing may not be the primary tool to accessing health needs, but it will certainly play an important supplementary role to other initiatives such as drug donations and UNITAID s patent pool [34].
10 References [1] WTO members and observers. (2008, July 23). Retrieved from [2] World Trade Organization, Information and Media Relations Division. Third Edition (2007). Understanding the WTO. Page 11. Retrieved (2010, March 17) from [3] World Trade Organization, Information and Media Relations Division. Third Edition (2007). Understanding the WTO. Page 17. Retrieved (2010, March 17) from [4] World Health Organization. (2005). Intellectual property protection: impact on public health. Access to Medicines, 19(3), Retrieved from [5] World Health Organization. (2009, March 13). WTO and the TRIPs agreement. Retrieved from [6] Id. [7] World Trade Organization. (2001, November 20). Declaration on the trips agreement and public health. Retrieved from [8] Id. [9] World Trade Organization, Information and Media Relations Division. (2006, September). Compulsory licensing of pharmaceuticals and trips. Retrieved from [10] Id. [11] UNAIDS, Initials. (2010, February 10). Brazil post offices join global HIV awareness campaign. Retrieved from es+join+global+hiv+awareness+campaign.asp [12] Ford et al. (2007). Sustaining access to antiretroviral therapy in the less-developed world: Lessons from Brazil and Thailand. Retrieved from al%20therapy%20-%20aids%2021-s4% %20pmid% pdf [13] Advisory Board Company and Kaiser Family Foundation,. (2008, September 19). Brazil to produce generic version of Merck's antiretroviral efavirenz. Retrieved from [14] Vide supra note 12
11 [15] World Trade Organization. (2006). Part II Standards concerning the availability, scope and use of Intellectual Property Rights. Retrieved from trips_04c_e.htm [16] Carlos Correa. (2004, April) Implementation of the WTO General Council Decision on Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. Retrieved from [17] ActionAid. (2003, September 5). The 30 August 2003 decision: Will it improve access to affordable medicines in poor countries?, TRIPs and Health. Retrieved from [18] Fergusson, I.F. (2007, November 5). The WTO, intellectual property rights, and the access to medicines controversy, page 6. Retrieved from [19] FDA News. (2007, October 8) Canada Notifies WTO About Compulsory License to Export Generic Drug. Retrieved from [20] Tsai, G. (2007) Canada's Access to Medicines Regime: Lessons for Compulsory Licensing Schemes under the WTO Doha Declaration. Retrieved from [21]Perez, M (2004, October) Intellectual property and pharmaceutical data exclusivity in the context of innovation and market access. Retrieved from [22] World Trade Organization. (2003, September 1). Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health. Retrieved from [23] Bird, R.C, & Subhash, J.C. (2008). The Global challenge of intellectual property rights. Page 224. Northampton: Edward Elgar Publishing Inc. [24] Bird, R.C, & Cahoy, D.R. (2008). The Impact of Compulsory Licensing on Foreign Direct Investment: A Collective Bargaining Approach. Page 19. Retreived from [25] Id. [26] Asfour, A. FDI in Egypt during 5 year. Retrieved from ring%25205%2520years.doc+fdi+egypt&cd=2&hl=en&ct=clnk&gl=ca [27] Love, J. (2007 May 6). Recent examples of the use of compulsory licenses on patents. Retrieved from
12 [28] Cawthorne et al. (2007 May) Access to drugs: the case of Abbott in Thailand. Retrieved from [29] Bhaopichitr et al. (2007) Thailand Economic Monitor, Page. World Bank Office Bangkok. Retreived from Monitor/2008april_tem.pdf [30] Mullin, T. (2003) AIDS, Anthrax, and compulsory licensing: Has the United States learned anything? A Comment on recent decisions on the international intellectual property rights of pharmaceutical patents. Retrieved from [31] Edwards, P. & Bateman, D. (2007) Stifling Debate in Ottawa. Retrieved from [32] Murray, J. (2009, December 2) Bill C-393 to pass second reading! Canada one step closer to providing affordable, generic medicines to developing countries! Retrieved from [33] Wasylycia-Leis, J. (2009, June) Hansard - 2nd reading of Bill C-393 (drugs for international humanitarian purposes). Retrieved from [34] UNITAID. The Medicines Patent Pool Initiative, Together to Heal. Retrieved from
The TRIPS Tightrope public health, innovation, incentives and access
International Federation of Pharmaceutical Manufacturers & Associations The TRIPS Tightrope public health, innovation, incentives and access Helsinki, 6 September 2013 1 IFPMA 2013 Definitions (I) Doha
More informationTRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4
TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY 1 12 14 March 2012 Pretoria, South Africa SESSION 4 ACCESS TO MEDICINE: COMMERCIALISATION, DISTRIBUTION, COMPETITION ----------------- Exploitation
More informationStanding Committee on the Law of Patents Twenty-Sixth Session
Standing Committee on the Law of Patents Twenty-Sixth Session Marco M. ALEMAN Director, Patent Law Division, WIPO Geneva, July 3 to 6, 2017 SCP/26/5 CONSTRAINTS FACED BY DEVELOPING COUNTRIES AND LEAST
More informationFixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers
Fixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers In this document: Questions 1 to 4 give a quick overview of CAMR and why it needs to be fixed. Questions 5 to 11 provide more in-depth,
More informationIPRs and Public Health: Lessons Learned Current Challenges The Way Forward
Local Pharmaceutical Production in Africa International Conference Cape Town, 4-6 April 2011 IPRs and Public Health: Lessons Learned Current Challenges The Way Forward Roger Kampf WTO Secretariat 1 Acknowledging
More informationDr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board
Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board Intellectual Property Rights in Preferential Trade Agreements Many Preferential Trade Agreements (PTAs) adopted
More information19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights
19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights Research FellowAkiko Kato This study examines the international protection
More informationTRIPS and Access to Medicines. The Story so far
TRIPS and Access to Medicines The Story so far TRIPS and Access to Medicines : A brief history 1981: HIV first clinically observed 1982-83: Named AIDS 1984: Discovery that it is caused by a virus 1986:
More informationUNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview
UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview December 2009 UNITAID Mission UNITAID's Mission Scale up access to treatment for HIV/AIDS, malaria and TB Leverage price reductions of quality
More informationVirtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12: 834-838. Health law Intellectual property and access to medicine for the poor by Tara Leevy, LLB, LLM India
More informationPATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS
PRB 99-46E PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS Margaret Smith Law and Government Division 30 March 2000 Revised 31 May 2000 PARLIAMENTARY RESEARCH BRANCH
More informationRegional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities
DEPARTMENT OF INTELLECTUAL PROPERTY MINISTRY OF COMMERCE Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities Topic 12: Which are Valid Grounds for a Compulsory
More informationIntellectual Property
Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness
More informationB) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:
INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is
More informationEstablishing a Development Agenda for the World Intellectual Property Organization
1 Establishing a Development Agenda for the World Intellectual Property Organization to be submitted by Brazil and Argentina to the 40 th Series of Meetings of the Assemblies of the Member States of WIPO
More informationTRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.
TRIPs & PATENTS Dr.Gopakumar G. Nair In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented. The events thereafter proved that inventions
More informationInternational IP. Prof. Eric E. Johnson. General Principles
International IP Prof. Eric E. Johnson ericejohnson.com General Principles territoriality Dependence, independence, central attack Procedural harmonization Substantive agreements National treatment Minima
More informationAn Essential Health and Biomedical R&D Treaty
An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third
More informationWTO NEGOTIATIONS ON TRIPS AND PUBLIC HEALTH: AN OVERVIEW. Jayashree Watal WTO Secretariat
WTO NEGOTIATIONS ON TRIPS AND PUBLIC HEALTH: AN OVERVIEW Jayashree Watal WTO Secretariat Outline Background to discussions in the TRIPS Council, including WHO-WTO Workshop on Differential Pricing and Financing
More informationGlobal strategy and plan of action on public health, innovation and intellectual property
SIXTY-FIRST WORLD HEALTH ASSEMBLY WHA61.21 Agenda item 11.6 24 May 2008 Global strategy and plan of action on public health, innovation and intellectual property The Sixty-first World Health Assembly,
More informationTRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries
Innovation, Creativity and IP Policy: An Indo-European Dialogue TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries Henning Grosse Ruse NUJS & MPI Collaborative
More informationAn overview of India's approach to key IP issues at home and abroad. Dr. Bona Muzaka King s College London
An overview of India's approach to key IP issues at home and abroad Dr. Bona Muzaka King s College London valbona.muzaka@kcl.ac.uk Why Intellectual Property? Why India? UNITAID (patent pools since 2008,
More informationCarnegie Endowment for International Peace
Carnegie Endowment for International Peace How the U.S. and India could Collaborate to Strengthen Their Bilateral Relationship in the Pharmaceutical Sector Second Panel: Exploring the Gilead-India Licensing
More informationTRIPS FLEXIBILITIES AND ACCESS TO MEDICINES
TRIPS FLEXIBILITIES AND ACCESS TO MEDICINES A European Approach Acknowledgements We are grateful to Ellen t Hoen for reviewing an earlier version of this brochure. Publisher Health Action International
More information2.5.2 NON-DISCRIMINATION (ARTICLE 27.1)
2.5.2 NON-DISCRIMINATION (ARTICLE 27.1) Article 27.1: Patentable Subject Matter... patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field
More informationEthiopia s Accession to World Trade Organization (WTO): The Need to Reform Ethiopian Patent Law to Facilitate Access to Medicine PART I
w w w. a b y s s i n i a l a w. c o m P a g e 1 Ethiopia s Accession to World Trade Organization (WTO): The Need to Reform Ethiopian Patent Law to Facilitate Access to Medicine Abstract As a country dealing
More informationProtecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence?
Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence? Henning Große Ruse International Investment Treaty Law and Arbitration Conference Sydney, 19-20 February
More informationAccess to Technology in the Post-2015 Development Agenda. Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center
Access to Technology in the Post-2015 Development Agenda Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center TECHNOLOGY IS ESSENTIAL FOR ACHIEVING SUSTAINABLE DEVELOPMENT MDG 8 ICT & Access
More informationChapter 15: Access to essential medicines, TRIPS and the patent system
Chapter 15: Access to essential medicines, TRIPS and the patent system SUMMARY POINTS All countries should develop a national medicines policy that includes a national list of essential medicines that
More informationA Brief History of IP & Patents: Drawing Lessons from the Past
A Brief History of IP & Patents: Drawing Lessons from the Past Asean Workshop on Compulsory Licensing to Increase Access to Antiretrovirals (ARVs) and Diagnostic Reagents Kuala Lumpur, Malaysia, May 2006
More informationBIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy
BIPF 2014 - Munich South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy Russell Bagnall Danie Dohmen 1 OVERVIEW Enforcement of Pharmaceutical Patents The Role Players Compulsory
More informationMagdalena Krawczyk. Compulsory Licensing of Pharmaceuticals since the Doha Declaration a Public Health Triumph or Failure? Abstract.
Zeszyty Naukowe Towarzystwa Doktorantów UJ Nauki Społeczne, Numer 15 (4/2016) Magdalena Krawczyk Jagiellonian University Faculty of Law and Administration The Intellectual Property Law Chair e-mail: magda.krawczyk@doctoral.uj.edu.pl
More informationTrips and Public Health: Solutions for Ensuring Global Access to Essential AIDS Medication n the Wake of Paragraph 6 Waiver
Journal of Contemporary Health Law & Policy Volume 25 Issue 1 Article 8 2008 Trips and Public Health: Solutions for Ensuring Global Access to Essential AIDS Medication n the Wake of Paragraph 6 Waiver
More informationTopic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs
Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs McLean Sibanda Chief Executive Officer - The Innovation Hub Second WIPO Inter-Regional
More information1. TRIPS, intellectual property rights and access to medicines a,b
UHC Technical brief 1. TRIPS, intellectual property rights and access to medicines a,b What is the TRIPS Agreement? The Agreement on Trade-Related Aspects of Intellectual Property Rights (or the TRIPS
More informationStanding Committee on the Law of Patents
E SCP/24/4 ORIGINAL: ENGLISH DATE: JUNE 29, 2016 Standing Committee on the Law of Patents Twenty-Fourth Session Geneva, June 27 to 30, 2016 PROPOSAL BY THE AFRICAN GROUP FOR A WIPO WORK PROGRAM ON PATENTS
More informationGENEVA WIPO GENERAL ASSEMBLY. Thirty-First (15 th Extraordinary) Session Geneva, September 27 to October 5, 2004
WIPO WO/GA/31/11 ORIGINAL: English DATE: August 27, 2004 WORLD INTELLECTUAL PROPERT Y O RGANI ZATION GENEVA E WIPO GENERAL ASSEMBLY Thirty-First (15 th Extraordinary) Session Geneva, September 27 to October
More informationRegional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities
REPUBLIC OF SOUTH AFRICA Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities Topic 7: Flexibilities Related to the Definition of Patentable
More informationFlexibilities in the Patent System
Flexibilities in the Patent System Dr. N.S. Gopalakrishnan Professor, HRD Chair on IPR School of Legal Studies, Cochin University of Science & Technology, Cochin, Kerala 1 Introduction The Context Flexibilities
More informationElements of a global strategy and plan of action
INTERGOVERNMENTAL WORKING GROUP A/PHI/IGWG/1/5 ON PUBLIC HEALTH, INNOVATION AND 8 December 2006 INTELLECTUAL PROPERTY Agenda item 2.3 Elements of a global strategy and plan of action Progress to date in
More informationBOOK REVIEW INTELLECTUAL PROPERTY, PHARMACEUTICALS AND PUBLIC HEALTH: ACCESS TO DRUGS IN DEVELOPING COUNTRIES
(2014) 11:3 SCRIPTed 332 BOOK REVIEW INTELLECTUAL PROPERTY, PHARMACEUTICALS AND PUBLIC HEALTH: ACCESS TO DRUGS IN DEVELOPING COUNTRIES By Kenneth C. Shadlen, Samira Guennif, Alenka Guzmán and N. Lalitha
More informationDraft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More informationHIV and co-infection medicines
IP and regulatory barriers in LMICs HIV and co-infection medicines APACC, 2018 Hongkong, June 2018 Monopolies linked to Prices Monopoly No monopoly One supplier Multiple suppliers No competition Competition
More informationCBD Request to WIPO on the Interrelation of Access to Genetic Resources and Disclosure Requirements
CBD Request to WIPO on the Interrelation of Access to Genetic Resources and Disclosure Requirements Establishing an adequate framework for a WIPO Response 1 Table of Contents I. Introduction... 1 II. Supporting
More informationSEMINAR: INTELLECTUAL PROPERTY ARRANGEMENTS: IMPLICATIONS FOR DEVELOPING COUNTRY PRODUCTIVE CAPABILITIES IN THE SUPPLY OF ESSENTIAL MEDICINES.
SEMINAR: INTELLECTUAL PROPERTY ARRANGEMENTS: IMPLICATIONS FOR DEVELOPING COUNTRY PRODUCTIVE CAPABILITIES IN THE SUPPLY OF ESSENTIAL MEDICINES Report The two-day seminar was opened by Mr. Khalil Hamdani,
More informationUS-ANDEAN FREE TRADE AGREEMENT IMPACT ON ACCESS TO MEDICINES AND HEALTH IN COLOMBIA
US-ANDEAN FREE TRADE AGREEMENT IMPACT ON ACCESS TO MEDICINES AND HEALTH IN COLOMBIA Germán Holguín General Director, Health Mission Foundation Bogotá, Colombia, November, 2005 ACCESS TO THE MEDICINES:
More informationTHE LEGALITY OF LOCAL PATENT WORKING REQUIREMENTS UNDER THE TRIPS AGREEMENT
THE LEGALITY OF LOCAL PATENT WORKING REQUIREMENTS UNDER THE TRIPS AGREEMENT Chia-Ling Lee * J.D. Graduate of Class 2013 Washington University in St. Louis School of Law ABSTRACT The balance between the
More informationAAAS Project on Science and Intellectual Property in the Public Interest
AAAS Project on Science and Intellectual Property in the Public Interest Bringing a public interest perspective to science and intellectual property issues, by: Examining the effects of IPRs on science
More informationPROTECTION OF INTELLECTUAL PROPERTY
Chapter 12 PROTECTION OF INTELLECTUAL PROPERTY OVERVIEW OF RULES In today s economic environment, intangible assets are becoming increasingly important. These assets, which are the result of human intellectual
More informationPATENTS, INTERNATIONAL TRADE LAW, & ACCESS TO ESSENTIAL MEDICINES
PATENTS, INTERNATIONAL TRADE LAW, & ACCESS TO ESSENTIAL MEDICINES RICHARD ELLIOTT, M ARIE-HÉLÈNE BONIN & CAROL DEVINE What is the issue? Currently, over 42 million people worldwide have HIV, and 95% of
More informationDraft global strategy on public health, innovation and intellectual property
IGWG: Outcome document at 14.00 hours, Saturday 3 May 2008 Draft global strategy on public health, innovation and intellectual property The context 1. In resolution WHA59.24 the Health Assembly recognized
More informationIntellectual Property and Public Health - International Framework and Recent Developments in WIPO: SCP and CDIP
Intellectual Property and Public Health - International Framework and Recent Developments in WIPO: SCP and CDIP WTO-ESCAP-IIUM REGIONAL WORKSHOP ON IP AND PUBLIC HEALTH AND ENVIRONMENT PLOICY FOR THE ASIAN
More informationNitya Nanda. The Energy and Resources Institute (TERI)
Nitya Nanda The Energy and Resources Institute (TERI) Arguments for and against patent protection The climate change context Perspectives on IPR and technology transfer Patent regimes in developing countries
More informationPublic Hearings Concerning the Evolving Intellectual Property Marketplace
[Billing Code: 6750-01-S] FEDERAL TRADE COMMISSION Public Hearings Concerning the Evolving Intellectual Property Marketplace AGENCY: Federal Trade Commission. ACTION: Notice of Public Hearings SUMMARY:
More informationThe stakes within diverse global policy deliberations concerning treatment of Intellectual Property related to standard-setting
The stakes within diverse global policy deliberations concerning treatment of Intellectual Property related to standard-setting ANSI CMF/ICSCA Meeting Agenda 3.4 Miami, Florida: April 10, 2008 Presented
More informationexceptional circumstance:
STATEMENT OF ANALYSIS OF DETERMINATION OF EXCEPTIONAL CIRCUMSTANCES FOR WORK PROPOSED UNDER THE SOLID STATE ENERGY CONVERSION ALLIANCE (SECA) PILOT PROGRAM For the reasons set forth below, the Department
More informationUNITED STATES JOINT SUBMISSION TO THE UN UNIVERSAL PERIODIC REVIEW NINTH SESSION OF THE HRC UPR WORKING GROUP NOVEMBER DECEMBER 2010
UNITED STATES JOINT SUBMISSION TO THE UN UNIVERSAL PERIODIC REVIEW NINTH SESSION OF THE HRC UPR WORKING GROUP NOVEMBER DECEMBER 2010 American University Washington College of Law s Program on Information
More informationThe FTAA, Access to HIV/AIDS Treatment, and Human Rights A Human Rights Watch Briefing Paper
HIV/AIDS & Human Rights Program The FTAA, Access to HIV/AIDS Treatment, and Human Rights A Human Rights Watch Briefing Paper October 29, 2002 I. Introduction Less than a year after the signing of the 2001
More informationWIPO NATIONAL WORKSHOP FOR PATENT LAWYERS
ORIGINAL: English DATE: May 1997 GOVERNMENT OF THE FEDERAL DEMOCRATIC REPUBLIC OF ETHIOPIA WORLD INTELLECTUAL PROPERTY ORGANIZATION WIPO NATIONAL WORKSHOP FOR PATENT LAWYERS organized by the World Intellectual
More informationTRIPS and Pharmaceutical Patents:
Lauri Kuosmanen TRIPS and Pharmaceutical Patents: Effects on Access to Essential Medicine and Innovation Helsinki Metropolia University of Applied Sciences Bachelor of Business Administration European
More informationIndian Pharmaceutical Alliance. Responses to the issues raised in the Discussion Paper on the Utility Model
Responses to the issues raised in the Discussion Paper on the Utility Model 30 June 2011 1 PREFACE The Department of Industrial Policy and Promotion, Ministry of Commerce has published a Discussion Paper
More informationSofosbuvir Patent Oppositions at European Patent Office
Challenging patent system in High Income Countries Sofosbuvir Patent Oppositions at European Patent Office Olivier Maguet Médecins du Monde, Drug Pricing Campaign WHS 2017, Sao Paulo, Options for countries
More informationCOMPLIANCE OF CANADA S UTILITY DOCTRINE WITH INTERNATIONAL MINIMUM STANDARDS OF PATENT PROTECTION
COMPLIANCE OF CANADA S UTILITY DOCTRINE WITH INTERNATIONAL MINIMUM STANDARDS OF PATENT PROTECTION Jerome H. Reichman Duke Law School April 11, 2014 1 E. Richard Gold & Michael Short The Promise of the
More informationPatent Working Requirements Historical and Comparative Perspectives
Patent Working Requirements Historical and Comparative Perspectives Marketa Trimble Professor of Law William S. Boyd School of Law Patent Sovereignty and International Law UC Irvine School of Law October
More information4. Vision 2: Providing innovative drugs to 8 billion people worldwide
4. Vision 2: Providing innovative drugs to 8 billion people worldwide Strategic points for realizing the vision Responding to diverse needs and issues [Advanced countries] Promoting understanding of the
More informationChanging role of the State in Innovative Activity The Indian Experience. Sunil Mani
Changing role of the State in Innovative Activity The Indian Experience Sunil Mani Outline The two manifestations of state intervention Manifestation 1: State involved directly in the creation of new technologies
More informationIntellectual Property Rights and Development CARLOS M. CORREA
Intellectual Property Rights and Development CARLOS M. CORREA Proposal by Argentina and Brazil (2004) IP protection is a policy instrument the operation of which may, in actual practice, produce benefits
More informationTrade, TRIPS+ & Access to Medicines
Trade, TRIPS+ & Access to Medicines Global Health Summer School Berlin, 20 September 2013 Tessel Mellema Health Action International (HAI) Europe This document arises f rom the HAI Europe s Operating Grant
More informationAccess to Medicines, Patent Information and Freedom to Operate
TECHNICAL SYMPOSIUM DATE: JANUARY 20, 2011 Access to Medicines, Patent Information and Freedom to Operate World Health Organization (WHO) Geneva, February 18, 2011 (preceded by a Workshop on Patent Searches
More informationIP Strategies to Enhance Competitiveness: India s Experience
IP Strategies to Enhance Competitiveness: India s Experience N. N. Prasad Wednesday July 15, 2009 Innovation in Brazil, India and South Africa: A New Drive for Economic Growth and Development Strategy
More informationHistorical Background, General Provisions and Basic Principles of the TRIPS Agreement and Transitional Arrangements*
J:mrnal ofinoollectual Property Rights Vol 3 March 1998 pp 68-73 Historical Background, General Provisions and Basic Principles of the TRIPS Agreement and Transitional Arrangements* Mart Leesti Former
More informationLAW ON TECHNOLOGY TRANSFER 1998
LAW ON TECHNOLOGY TRANSFER 1998 LAW ON TECHNOLOGY TRANSFER May 7, 1998 Ulaanbaatar city CHAPTER ONE COMMON PROVISIONS Article 1. Purpose of the law The purpose of this law is to regulate relationships
More informationThe TRIPS Agreement and access to medicines: who are the main losers?
Farkas, B. (ed) 2011: Studies in International Economics and Finance. JATEPress, Szeged, pp. 157 179. The TRIPS Agreement and access to medicines: who are the main losers? That, as we enjoy great advantages
More informationA NEW INCENTIVE SYSTEM FOR TECHNOLOGICAL INNOVATION IN DEVELOPING COUNTRIES
A NEW INCENTIVE SYSTEM FOR TECHNOLOGICAL INNOVATION IN DEVELOPING COUNTRIES Miguel A. Maito Eduardo Franciosi Introduction This work has been inspired by the analysis and discussion of Professor Joseph
More informationThe Contribution of Intellectual Property to Facilitating the Transfer of Environmentally Sound Technology
Report The Contribution of Intellectual Property to Facilitating the Transfer of Environmentally Sound Technology Tuesday, 12 May 2015, Java Hill, Crozet, France Nina Fink In the line of the use and transfer
More informationIntellectual Property Policy. DNDi POLICIES
Intellectual Property Policy DNDi POLICIES DNDi hereby adopts the following intellectual property (IP) policy: I. Preamble The mission of DNDi is to develop safe, effective and affordable new treatments
More informationIndependence - Freedom - Happiness. Hanoi, 20 March 1996
NATIONAL ASSEMBLY SOCIALIST REPUBLIC OF VIETNAM Independence - Freedom - Happiness Hanoi, 20 March 1996 MINERAL LAW Being natural resources which are an important asset of the nation and which are generally
More informationTRIPS and Access to Medicines. WR Briefing
TRIPS and Access to Medicines WR Briefing Outline What is TRIPS How does it affect access to medicines What are the TRIPS flexibilities? What are extra-trips provisions? How do the extra-trips provisions
More informationWIPO Development Agenda
WIPO Development Agenda William New William New Intellectual Property Watch Geneva wnew@ip-watch.ch WIPO Development Agenda* Background to Agreement 2007 Development Agenda Availability of Information
More informationTrans-Pacific Partnership Lost Important IP Provisions
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Trans-Pacific Partnership Lost Important
More informationITI Comment Submission to USTR Negotiating Objectives for a U.S.-Japan Trade Agreement
ITI Comment Submission to USTR-2018-0034 Negotiating Objectives for a U.S.-Japan Trade Agreement DECEMBER 3, 2018 Introduction The Information Technology Industry Council (ITI) welcomes the opportunity
More informationDeveloping Countries in the Globalization of Pharmaceutical Patenting
Developing Countries in the Globalization of Pharmaceutical Patenting Ken Shadlen Department of International Development London School of Economics and Political Science (LSE) Stanford University Library
More informationIntellectual Property and Genetic Resources: Relationship with Relevant International Instruments
South Unity, South Progress. Intellectual Property and Genetic Resources: Relationship with Relevant International Instruments Viviana Munoz Tellez Coordinator Development, Innovation and Intellectual
More information11th Annual Patent Law Institute
INTELLECTUAL PROPERTY Course Handbook Series Number G-1316 11th Annual Patent Law Institute Co-Chairs Scott M. Alter Douglas R. Nemec John M. White To order this book, call (800) 260-4PLI or fax us at
More informationThe Standardization and the Patent Issue in Telemedicine
The Standardization and the Patent Issue in Telemedicine Makoto ISHIKAWA Associate Professor Kyoto University of Education Standardization in telemedicine Telemedicine is the medical care using information
More informationMedical Innovation Changing Business Models. Geneva, 5 July 2013
Medical Innovation Changing Business Models (A joint technical symposium by WHO, WIPO and WTO) Geneva, 5 July 2013 Richard Wilder Associate General Counsel Global Health Funding Options and IP Grants:
More informationParallel Importation and the Exhaustion of Rights Principle under the TRIPS Agreement and the Doha Declaration
Parallel Importation and the Exhaustion of Rights Principle under the TRIPS Agreement and the Doha Declaration -Yetunde Okojie 1 Introduction and the Concept of Parallel Importation: Parallel importation
More informationPROPOSAL TEMPLATE. Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments
PROPOSAL TEMPLATE Proposal Name: Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments Submitted by: Pr. Patrick Leoni - Euromed Management (France) E-mail: patrick.leoni@euromed-management.com
More informationFree Trade Agreements on Public Health
UNDP, UNAIDS Issue BRIEF 2012 The Potential Impact of Free Trade Agreements on Public Health The Potential Impact of Free Trade Agreements on Public Health UNDP, UNAIDS UNAIDS / JC2349E (English original,
More informationEconomics of IPRs and patents
Economics of IPRs and patents TIK, UiO 2016 Bart Verspagen UNU-MERIT, Maastricht verspagen@merit.unu.edu 3. Intellectual property rights The logic of IPRs, in particular patents The economic design of
More informationStanding Committee on the Law of Patents
E SCP/18/INF/3 ORIGINAL: ENGLISH DATE: APRIL 11, 2012 Standing Committee on the Law of Patents Eighteenth Session Geneva, May 21 to 25, 2012 PATENTS AND HEALTH: COMMENTS RECEIVED FROM MEMBERS AND OBSERVERS
More informationWHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO
WHO workshop on IP and Vaccines Geneva 19 th -20 th April 2004 Introduction to the IP issues Christopher Garrison Consultant to WHO Vaccine access, R&D and technology transfer issues are intimately linked
More informationTranslation University of Tokyo Intellectual Property Policy
Translation University of Tokyo Intellectual Property Policy February 17, 2004 Revised September 30, 2004 1. Objectives The University of Tokyo has acknowledged the roles entrusted to it by the people
More informationRegional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities
REPUBLIC OF SOUTH AFRICA Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities Topic 15: The Impact of National Exhaustion of Rights on the
More informationIssues and Possible Reforms in the U.S. Patent System
Issues and Possible Reforms in the U.S. Patent System Bronwyn H. Hall Professor in the Graduate School University of California at Berkeley Overview Economics of patents and innovations Changes to US patent
More informationTRIPS-Plus Provisions and Access to Technologies:
TRIPS-Plus Provisions and Access to Technologies: Implications for the Trans-Pacific Partnership Walter G. Park, American University 11 May 2012 Outline Notion of Optimal IPRs IPRs and Technology Transfer
More informationTopic 2: The Critical Role of IP Policies in Modern Economies
Topic 2: The Critical Role of IP Policies in Modern Economies McLean Sibanda Partner: Sibanda & Zantwijk Attorneys, South Africa THE ROLE OF INTELLECTUAL PROPERTY OFFICES (IPOs) IN PROMOTING INNOVATION,
More informationAccess to current products and innovation for the future- Some community Thoughts. Kenly Sikwese Geneva 1 November 2011
Access to current products and innovation for the future- Some community Thoughts Kenly Sikwese Geneva 1 November 2011 Financing the response Current ART successes have been predicated on sustained new
More information372 index. predominantly for supply of domestic market 113, 132 3, 184 5, 186; remedying anticompetitive
INDEX acceding countries 23 Access to Medicines, Patent Information and Freedom to Operate (WHO/ WIPO/WTO) 195 Access to Medicines: Pricing and Procurement Practices (WHO/WIPO/WTO) 195 Agreement on Trade-Related
More informationTrade Policy III - WTO and Case Studies
Trade Policy III - WTO and Case Studies International Trade Theory ITAM Rahul Giri (ITAM) Trade Policy III - WTO and Case Studies 1 / 19 Objective Discuss the evolution of the World Trade Organization.
More information